Quality of life in chronic hypoparathyroidism patients
Part of Hormones & metabolism clinical trials.
This study looks at how chronic hypoparathyroidism affects daily life and well-being. It may help understand the condition better and improve support for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must be fluent in Greek
- You must have chronic hypoparathyroidism, meaning you need calcium and active vitamin D treatment for more than 12 months
- Your condition must be well controlled with current treatment
- You must not be over 80 years old
- You must not have cancer, a psychiatric illness, or cognitive impairment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with hypoparathyroidism to better understand what symptoms and lab levels change over time. It may help doctors plan future treatments by learning the natural course of the condition, even if you already take standard medicines.
This study tests a new medicine called encaleret for people with chronic hypoparathyroidism, a condition where the body has too little parathyroid hormone, leading to low calcium levels. The medicine aims to improve calcium balance and reduce the need for daily calcium and vitamin D supplements.
This is a registry (data collection) study that gathers information about people diagnosed with chronic hypoparathyroidism in France. It helps researchers better understand how common it is and what it looks like in real life.
This study is a registry that collects health information from people with chronic low parathyroid hormone (hypoparathyroidism) or pseudohypoparathyroidism. It aims to better understand these conditions and improve future care. You may join if you are an adult living in Germany.
This trial tests a new treatment to help people with hypoparathyroidism (a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels) manage their calcium better. It aims to reduce the need for calcium and vitamin D supplements.
This trial is for adults with hypoparathyroidism who are already taking a drug called palopegteriparatide (TransCon PTH) at a certain dose. It tests whether higher doses of this drug can better control calcium levels and reduce the need for other supplements.
Hear when a new Hypoparathyroidism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.